Galliprant® (grapiprant tablets)

Start Seeing Osteoarthritis (OA) From A Different Perspective

Galliprant® (grapiprant tablets) provides targeted pain relief from the earliest diagnosed stages of canine OA.

  • A first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID that specifically targets the EP4 receptor1
  • Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs
  • Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,2
  • Suitable for canine patients as young as 9 months of age and allows most dogs to be dosed with a whole or half tablet

In co-promotion with Elanco Animal Health, a division of Eli Lilly and Company. 

IMPORTANT SAFETY INFORMATION

  • GALLIPRANT® (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose.
  • Do not use in dogs that have a hypersensitivity to grapiprant.
  • If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied.
  • The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease.
  • The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy.

Click here for full prescribing information.

1. Kirkby Shaw, K, Rausch-Derra, LC, and Rhodes, L. 2016. “Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.” Veterinary Medicine and Science. 2.1: 3-9.
2. Rausch-Derra, LC, Huebner, M, and Rhodes, L. 2015. “Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs.” AJVR. 76.10: 853-859.

USCACGLP00064(1)